{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:05:50Z","timestamp":1789362350028,"version":"build-2803163510"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"DOI":"10.1038\/s41401-026-01923-5","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:00:42Z","timestamp":1789362042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structural basis for small-molecule agonism at GCGR and GIPR via a conserved intracellular allosteric site"],"prefix":"10.1038","author":[{"given":"Qian","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Eric Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"1923_CR1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12272-011-0721-z","volume":"34","author":"HS Moon","year":"2011","unstructured":"Moon HS, Kim MK, Son MH. The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. Arch Pharm Res. 2011;34:1041\u20133. https:\/\/doi.org\/10.1007\/s12272-011-0721-z","journal-title":"Arch Pharm Res"},{"key":"1923_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"9","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:234 https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"key":"1923_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.2337\/dbi21-0002","volume":"70","author":"RJ Samms","year":"2021","unstructured":"Samms RJ, Sloop KW, Gribble FM, Reimann F, Adriaenssens AE. GIPR function in the central nervous system: implications and novel perspectives for GIP-based therapies in treating metabolic disorders. Diabetes. 2021;70:1938\u201344. https:\/\/doi.org\/10.2337\/dbi21-0002","journal-title":"Diabetes"},{"key":"1923_CR4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fphys.2019.00413","volume":"10","author":"KD Galsgaard","year":"2019","unstructured":"Galsgaard KD, Pedersen J, Knop FK, Holst JJ, Wewer Albrechtsen NJ. Glucagon receptor signaling and lipid metabolism. Front Physiol. 2019;10:413 https:\/\/doi.org\/10.3389\/fphys.2019.00413","journal-title":"Front Physiol"},{"key":"1923_CR5","doi-asserted-by":"publisher","first-page":"101533","DOI":"10.1016\/j.molmet.2022.101533","volume":"63","author":"PJ Knerr","year":"2022","unstructured":"Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hj\u00f8llund KR, He Y, et al. Next-generation GLP-1\/GIP\/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533 https:\/\/doi.org\/10.1016\/j.molmet.2022.101533","journal-title":"Mol Metab"},{"key":"1923_CR6","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1016\/j.cell.2024.06.003","volume":"187","author":"CM Kusminski","year":"2024","unstructured":"Kusminski CM, Perez-Tilve D, M\u00fcller TD, DiMarchi RD, Tsch\u00f6p MH, Scherer PE. Transforming obesity: the advancement of multi-receptor drugs. Cell. 2024;187:3829\u201353. https:\/\/doi.org\/10.1016\/j.cell.2024.06.003","journal-title":"Cell."},{"key":"1923_CR7","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292 https:\/\/doi.org\/10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol"},{"key":"1923_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13098-025-01623-w","volume":"17","author":"M Movahednasab","year":"2025","unstructured":"Movahednasab M, Dianat-Moghadam H, Khodadad S, Nedaeinia R, Safabakhsh S, Ferns G, et al. GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation. Diabetol Metab Syndr. 2025;17:60 https:\/\/doi.org\/10.1186\/s13098-025-01623-w","journal-title":"Diabetol Metab Syndr"},{"key":"1923_CR9","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","volume":"5","author":"R Nogueiras","year":"2023","unstructured":"Nogueiras R, Nauck MA, Tschop MH. Gut hormone co-agonists for the treatment of obesity: from bench to bedside. Nat Metab. 2023;5:933\u201344. https:\/\/doi.org\/10.1038\/s42255-023-00812-z","journal-title":"Nat Metab"},{"key":"1923_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJMoa2504214","volume":"393","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, et al. Once-monthly maridebart cafraglutide for the treatment of obesity - a phase 2 trial. N Engl J Med. 2025;393:843\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2504214","journal-title":"N Engl J Med"},{"key":"1923_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, Wu Q, Du Y, Gurbuz S, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389:514\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"1923_CR12","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","volume":"392","author":"L Ji","year":"2025","unstructured":"Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al. Once-weekly mazdutide in Chinese adults with obesity or overweight. N Engl J Med. 2025;392:2215\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2411528","journal-title":"N Engl J Med"},{"key":"1923_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"1923_CR14","doi-asserted-by":"publisher","unstructured":"Douros JD, Mowery SA, Knerr PJ. The premise of the paradox: examining the evidence that motivated GIPR agonist and antagonist drug development programs. J Clin Med. 2025; 14 https:\/\/doi.org\/10.3390\/jcm14113812.","DOI":"10.3390\/jcm14113812"},{"key":"1923_CR15","doi-asserted-by":"publisher","first-page":"100127","DOI":"10.1016\/j.obpill.2024.100127","volume":"12","author":"W Ghusn","year":"2024","unstructured":"Ghusn W, Hurtado MD. Glucagon-like receptor-1 agonists for obesity: weight loss outcomes, tolerability, side effects, and risks. Obes Pillars. 2024;12:100127 https:\/\/doi.org\/10.1016\/j.obpill.2024.100127","journal-title":"Obes Pillars"},{"key":"1923_CR16","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/cbdd.12055","volume":"81","author":"DJ Craik","year":"2013","unstructured":"Craik DJ, Fairlie DP, Liras S, Price D. The future of peptide-based drugs. Chem Biol Drug Des. 2013;81:136\u201347. https:\/\/doi.org\/10.1111\/cbdd.12055","journal-title":"Chem Biol Drug Des"},{"key":"1923_CR17","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.3390\/ijms19092714","volume":"19","author":"S La Manna","year":"2018","unstructured":"La Manna S, Di Natale C, Florio D, Marasco D. Peptides as therapeutic agents for inflammatory-related diseases. Int J Mol Sci. 2018;19:2714 https:\/\/doi.org\/10.3390\/ijms19092714","journal-title":"Int J Mol Sci"},{"key":"1923_CR18","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1021\/acs.jmedchem.9b01743","volume":"63","author":"Y Nishimura","year":"2020","unstructured":"Nishimura Y, Esaki T, Isshiki Y, Furuta Y, Mizutani A, Kotake T, et al. Lead optimization and avoidance of reactive metabolite leading to PCO371, a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) agonist. J Med Chem. 2020;63:5089\u201399. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01743","journal-title":"J Med Chem"},{"key":"1923_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1902-z","volume":"577","author":"P Zhao","year":"2020","unstructured":"Zhao P, Liang YL, Belousoff MJ, Deganutti G, Fletcher MM, Willard FS, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020;577:432\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1902-z","journal-title":"Nature."},{"key":"1923_CR20","doi-asserted-by":"publisher","first-page":"102156","DOI":"10.1016\/j.xcrm.2025.102156","volume":"6","author":"R Rodriguez","year":"2025","unstructured":"Rodriguez R, Hergarden A, Krishnan S, Morales M, Lam D, Tracy T, et al. Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R\/GIPR biased agonism yielding greater efficacy. Cell Rep Med. 2025;6:102156 https:\/\/doi.org\/10.1016\/j.xcrm.2025.102156","journal-title":"Cell Rep Med"},{"key":"1923_CR21","doi-asserted-by":"publisher","first-page":"100133","DOI":"10.1074\/jbc.RA120.016334","volume":"296","author":"B Jones","year":"2021","unstructured":"Jones B, McGlone ER, Fang Z, Pickford P, Corr\u00eaa IR Jr, Oishi A, et al. Genetic and biased agonist-mediated reductions in beta-arrestin recruitment prolong cAMP signaling at glucagon family receptors. J Biol Chem. 2021;296:100133 https:\/\/doi.org\/10.1074\/jbc.RA120.016334","journal-title":"J Biol Chem"},{"key":"1923_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/dom.15288","volume":"26","author":"CE Hinds","year":"2024","unstructured":"Hinds CE, Peace E, Chen S, Davies I, El Eid L, Tomas A, et al. Abolishing beta-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists. Diab Obes Metab. 2024;26:65\u201377. https:\/\/doi.org\/10.1111\/dom.15288","journal-title":"Diab Obes Metab"},{"key":"1923_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bph.15497","volume":"179","author":"B Jones","year":"2022","unstructured":"Jones B. The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol. 2022;179:492\u2013510. https:\/\/doi.org\/10.1111\/bph.15497","journal-title":"Br J Pharmacol"},{"key":"1923_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010919-023301","volume":"60","author":"D Wootten","year":"2020","unstructured":"Wootten D, Miller LJ. Structural basis for allosteric modulation of class B G protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2020;60:89\u2013107. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010919-023301","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1923_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-06467-w","volume":"621","author":"LH Zhao","year":"2023","unstructured":"Zhao LH, He Q, Yuan Q, Gu Y, He X, Shan H, et al. Conserved class B GPCR activation by a biased intracellular agonist. Nature. 2023;621:635\u201341. https:\/\/doi.org\/10.1038\/s41586-023-06467-w","journal-title":"Nature."},{"key":"1923_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41586-023-06169-3","volume":"618","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Kawakami K, Kusakizako T, Tomita A, Nishimura M, Sawada K, et al. Class B1 GPCR activation by an intracellular agonist. Nature. 2023;618:1085\u201393. https:\/\/doi.org\/10.1038\/s41586-023-06169-3","journal-title":"Nature."},{"key":"1923_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1126\/science.aav7942","volume":"364","author":"LH Zhao","year":"2019","unstructured":"Zhao LH, Ma S, Sutkeviciute I, Shen DD, Zhou XE, de Waal PW, et al. Structure and dynamics of the active human parathyroid hormone receptor-1. Science. 2019;364:148\u201353. https:\/\/doi.org\/10.1126\/science.aav7942","journal-title":"Science."},{"key":"1923_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41421-024-00679-8","volume":"10","author":"Q He","year":"2024","unstructured":"He Q, Yuan Q, Shan H, Wu C, Gu Y, Wu K, et al. Mechanisms of ligand recognition and activation of melanin-concentrating hormone receptors. Cell Discov. 2024;10:48 https:\/\/doi.org\/10.1038\/s41421-024-00679-8","journal-title":"Cell Discov"},{"key":"1923_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/acschembio.5b00753","volume":"11","author":"AS Dixon","year":"2016","unstructured":"Dixon AS, Schwinn MK, Hall MP, Zimmerman K, Otto P, Lubben TH, et al. NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. ACS Chem Biol. 2016;11:400\u20138. https:\/\/doi.org\/10.1021\/acschembio.5b00753","journal-title":"ACS Chem Biol"},{"key":"1923_CR30","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nature10361","volume":"477","author":"SG Rasmussen","year":"2011","unstructured":"Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature. 2011;477:549\u201355. https:\/\/doi.org\/10.1038\/nature10361","journal-title":"Nature."},{"key":"1923_CR31","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41467-022-28683-0","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao F, Zhou Q, Cong Z, Hang K, Zou X, Zhang C, et al. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors. Nat Commun. 2022;13:1057 https:\/\/doi.org\/10.1038\/s41467-022-28683-0","journal-title":"Nat Commun"},{"key":"1923_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/acsptsci.8b00017","volume":"1","author":"YL Liang","year":"2018","unstructured":"Liang YL, Zhao P, Draper-Joyce C, Baltos JA, Glukhova A, Truong TT, et al. Dominant negative G proteins enhance formation and purification of agonist-GPCR-G protein complexes for structure determination. ACS Pharmacol Transl Sci. 2018;1:12\u201320. https:\/\/doi.org\/10.1021\/acsptsci.8b00017","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1923_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41421-024-00649-0","volume":"10","author":"Z Cong","year":"2024","unstructured":"Cong Z, Zhao F, Li Y, Luo G, Mai Y, Chen X, et al. Molecular features of the ligand-free GLP-1R, GCGR and GIPR in complex with Gs proteins. Cell Discov. 2024;10:18 https:\/\/doi.org\/10.1038\/s41421-024-00649-0","journal-title":"Cell Discov"},{"key":"1923_CR34","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","volume":"80","author":"X Zhang","year":"2020","unstructured":"Zhang X, Belousoff MJ, Zhao P, Kooistra AJ, Truong TT, Ang SY, et al. Differential GLP-1R binding and activation by peptide and non-peptide agonists. Mol Cell. 2020;80:485\u2013500.e487. https:\/\/doi.org\/10.1016\/j.molcel.2020.09.020","journal-title":"Mol Cell"},{"key":"1923_CR35","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1073\/pnas.1221585110","volume":"110","author":"D Wootten","year":"2013","unstructured":"Wootten D, Simms J, Miller LJ, Christopoulos A, Sexton PM. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. Proc Natl Acad Sci USA. 2013;110:5211\u20136. https:\/\/doi.org\/10.1073\/pnas.1221585110","journal-title":"Proc Natl Acad Sci USA"},{"key":"1923_CR36","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/prot.26256","volume":"90","author":"HN Do","year":"2022","unstructured":"Do HN, Haldane A, Levy RM, Miao Y. Unique features of different classes of G-protein-coupled receptors revealed from sequence coevolutionary and structural analysis. Proteins. 2022;90:601\u201314. https:\/\/doi.org\/10.1002\/prot.26256","journal-title":"Proteins."},{"key":"1923_CR37","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1126\/science.aaz5346","volume":"367","author":"A Qiao","year":"2020","unstructured":"Qiao A, Han S, Li X, Li Z, Zhao P, Dai A, et al. Structural basis of Gs and Gi recognition by the human glucagon receptor. Science. 2020;367:1346\u201352. https:\/\/doi.org\/10.1126\/science.aaz5346","journal-title":"Science."},{"key":"1923_CR38","doi-asserted-by":"publisher","first-page":"e68719","DOI":"10.7554\/eLife.68719","volume":"10","author":"F Zhao","year":"2021","unstructured":"Zhao F, Zhang C, Zhou Q, Hang K, Zou X, Chen Y, et al. Structural insights into hormone recognition by the human glucose-dependent insulinotropic polypeptide receptor. Elife. 2021;10:e68719 https:\/\/doi.org\/10.7554\/eLife.68719","journal-title":"Elife."},{"key":"1923_CR39","doi-asserted-by":"publisher","first-page":"102365","DOI":"10.1016\/j.molmet.2026.102365","volume":"108","author":"D Perez-Tilve","year":"2026","unstructured":"Perez-Tilve D, Zhang F, Zhang Y, Lohman K, Sorrell J, Vick A, et al. GIPR:GCGR co-agonism restores normal weight in obese rodents. Mol Metab. 2026;108:102365 https:\/\/doi.org\/10.1016\/j.molmet.2026.102365","journal-title":"Mol Metab"},{"key":"1923_CR40","doi-asserted-by":"publisher","first-page":"e2303696120","DOI":"10.1073\/pnas.2303696120","volume":"120","author":"Y Li","year":"2023","unstructured":"Li Y, Zhou Q, Dai A, Zhao F, Chang R, Ying T, et al. Structural analysis of the dual agonism at GLP-1R and GCGR. Proc Natl Acad Sci USA. 2023;120:e2303696120 https:\/\/doi.org\/10.1073\/pnas.2303696120","journal-title":"Proc Natl Acad Sci USA"},{"key":"1923_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.str.2012.04.010","volume":"20","author":"E Chun","year":"2012","unstructured":"Chun E, Thompson AA, Liu W, Roth CB, Griffith MT, Katritch V, et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure. 2012;20:967\u201376. https:\/\/doi.org\/10.1016\/j.str.2012.04.010","journal-title":"Structure."},{"key":"1923_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.molcel.2020.01.013","volume":"77","author":"S Ma","year":"2020","unstructured":"Ma S, Shen Q, Zhao LH, Mao C, Zhou XE, Shen DD, et al. Molecular basis for hormone recognition and activation of corticotropin-releasing factor receptors. Mol Cell. 2020;77:669\u201380.e664. https:\/\/doi.org\/10.1016\/j.molcel.2020.01.013","journal-title":"Mol Cell"},{"key":"1923_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1107\/S2052252520000081","volume":"7","author":"J Zivanov","year":"2020","unstructured":"Zivanov J, Nakane T, Scheres SHW. Estimation of high-order aberrations and anisotropic magnification from cryo-EM data sets in RELION-3.1. IUCrJ. 2020;7:253\u201367. https:\/\/doi.org\/10.1107\/S2052252520000081","journal-title":"IUCrJ"},{"key":"1923_CR44","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.jsb.2015.08.008","volume":"192","author":"A Rohou","year":"2015","unstructured":"Rohou A, Grigorieff N. CTFFIND4: fast and accurate defocus estimation from electron micrographs. J Struct Biol. 2015;192:216\u201321. https:\/\/doi.org\/10.1016\/j.jsb.2015.08.008","journal-title":"J Struct Biol"},{"key":"1923_CR45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani A, Rubinstein JL, Fleet DJ, Brubaker MA. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods. 2017;14:290\u20136. https:\/\/doi.org\/10.1038\/nmeth.4169","journal-title":"Nat Methods"},{"key":"1923_CR46","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/s42003-021-02399-1","volume":"4","author":"R Sanchez-Garcia","year":"2021","unstructured":"Sanchez-Garcia R, Gomez-Blanco J, Cuervo A, Carazo JM, Sorzano COS, Vargas J, et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Commun Biol. 2021;4:874 https:\/\/doi.org\/10.1038\/s42003-021-02399-1","journal-title":"Commun Biol."},{"key":"1923_CR47","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41586-019-1923-7","volume":"577","author":"AW Senior","year":"2020","unstructured":"Senior AW, Evans R, Jumper J, Kirkpatrick J, Sifre L, Green T, et al. Improved protein structure prediction using potentials from deep learning. Nature. 2020;577:706\u201310. https:\/\/doi.org\/10.1038\/s41586-019-1923-7","journal-title":"Nature"},{"key":"1923_CR48","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03819-2","journal-title":"Nature."},{"key":"1923_CR49","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 2004;25:1605\u201312. https:\/\/doi.org\/10.1002\/jcc.20084","journal-title":"J Comput Chem"},{"key":"1923_CR50","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard TD, Huang CC, Meng EC, Pettersen EF, Couch GS, Morris JH, et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 2018;27:14\u201325. https:\/\/doi.org\/10.1002\/pro.3235","journal-title":"Protein Sci"},{"key":"1923_CR51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll TI. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr D Struct Biol. 2018;74:519\u201330. https:\/\/doi.org\/10.1107\/S2059798318002425","journal-title":"Acta Crystallogr D Struct Biol"},{"key":"1923_CR52","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. 2004;60:2126\u201332. https:\/\/doi.org\/10.1107\/S0907444904019158","journal-title":"Acta Crystallogr D"},{"key":"1923_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams PD, Afonine PV, Bunk\u00f3czi G, Chen VB, Davis IW, Echols N, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66:213\u201321. https:\/\/doi.org\/10.1107\/S0907444909052925","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01923-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01923-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:00:44Z","timestamp":1789362044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-026-01923-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":53,"alternative-id":["1923"],"URL":"https:\/\/doi.org\/10.1038\/s41401-026-01923-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HEX is a founder of Cascade Pharmaceutics. HEX\u00a0is the associate\u00a0editor-in-chief of the journal and was not involved in the peer review or the decision making of the article.\u00a0All other authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"During the preparation of this review, we utilized AI-assisted tools, including Gemini3 and ChatGPT, to aid in language refinement and writing clarity. All the content generated with these tools was carefully reviewed and edited by the authors, who take full responsibility for the final version of the manuscript.","order":2,"name":"Ethics","label":"Declaration of the use of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Ethics"}}]}}